Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 21, 2016

View Archived Issues

Allakos completes dosing in phase I trial of AK-001

FDA grants orphan drug designation to Thetis Pharmaceuticals' TP-252

Mifepristone granted .U.S orphan designation for ovarian cancer

Amarantus and Avant Diagnostics enter a letter of intent to merge diagnostics business unit

Primate models of retinal degeneration allow assessment of retinal transplantation

Glenmark updates pipeline data

Coprimary efficacy endpoints met in phase III trial of beloranib for Prader-Willi syndrome

Transgenomic launches new MX-ICP cancer panels

Novozymes forms an independent company to separate its biopharma activities

FDA approves sBLA for Arzerra as extended treatment of recurrent or progressive CLL

Enrollment open in phase I/II study of Cytori Cell Therapy

Novel stem cell therapy demonstrates preclinical efficacy in AD models

FDA grants breakthrough therapy designation for venetoclax in relapsed/refractory CLL

FDA approves Neulasta to treat radiation sickness

Launch of a new partnership focused on accelerating Alzheimer's treatment

Apatorsen misses PFS endpoint in phase II NSCLC trial

Sunshine Lake Pharma patents 5-HT6 receptor antagonists

Ensysce Biosciences and Signature Therapeutics complete merger

Spero Therapeutics describes antibacterials

Daiichi Sankyo develops LRS inhibitors

The University of Tokyo divulges P2Y10 agonists

Kuros Biosurgery Holding closes merger with Cytos Biotechnology

UAB Research Foundation reports retinoid RXR agonists

Cosentyx available in U.S. for treatment of ankylosing spondylitis and psoriatic arthritis

New sound wave technology may revolutionize nebulizers

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026